The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.
Open accessAbstract
Platinum compounds induce apoptosis in malignant cells and are used extensively in the treatment of cancer. Total dose is limited by development of a sensory neuropathy. We now demonstrate that when rats are administered cisplatin (2 mg/kg i.p. for 5 d), primary sensory neurons in the dorsal root ganglion die by apoptosis. This was reproduced by exposure of dorsal root ganglion neurons and PC12 cells to cisplatin (3 microg/ml) in vitro. Apoptosis was confirmed by electron microscopy, DNA laddering, and inhibition by the caspase inhibitor z-VAD.fmk (100 microM). Cell death in vitro was preceded by upregulation of cyclin D1, cdk4, and increased phosphorylation of retinoblastoma protein; all are indicators of cell cycle advancement. The level of p16(INK4a), an endogenous inhibitor of the cyclin D1/cdk4 complex decreased. Exposure of PC12 cells and dorsal root ganglion neurons to increased levels of nerve growth factor (100 ng/ ml) prevented both apoptosis and upregulation of the cell cycle markers. Cancer cells without nerve growth factor receptors (gp140TrkA) were not protected by the neurotrophin. This indicated that cisplatin may kill cancer cells and neurons by a similar mechanism. In postmitotic neurons, this involves an attempt to re-enter the cell cycle resulting in apoptosis which is specifically prevented by nerve growth factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980 · cited 1×
“As cells enter the cycle from quiescence (G0), one or more D-type cyclins (D1, D2, D3) are induced as part of the delayed early response to extracellular stimulation; both their synthesis and assembly with their catalytic partners, cdk4 and cdk6, depend on this external stimulation (61).”
BackgroundPhysical interaction of the retinoblastoma protein with human D cyclins
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 744
Lévi, F., Zidani, R., & Misset, J.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03358-8 · Cited by 701
Freeman, R. S., Estus, S., & Johnson, E. M. (1994) · Neuron · doi:10.1016/0896-6273(94)90276-3 · Cited by 573
Role for Ceramide in Cell Cycle Arrest
Jayadev, S., Liu, B., Bielawska, A. E., Lee, J. Y., Nazaire, F., Pushkareva, M. Y., Obeid, L. M., & Hannun, Y. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.5.2047 · Cited by 486
Function of a human cyclin gene as an oncogene.
Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A., & Weinberg, R. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.709 · Cited by 454
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Chemotherapy of Neoplastic Diseases
Calabresi, P. A., & Welch, A. D. (1962) · Annual Review of Medicine · doi:10.1146/annurev.me.13.020162.001051 · Cited by 419
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Cyclin D1 is an essential mediator of apoptotic neuronal cell death.
Kranenburg, O., van der Eb, A. J., & Zantema, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00332.x · Cited by 379
Peripheral sensory neuropathy and cisplatin chemotherapy
Roelofs, R. I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984) · Neurology · doi:10.1212/wnl.34.7.934 · Cited by 370
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.
Lees, J. A., Buchkovich, K. J., Marshak, D. R., Anderson, C. W., & Harlow, E. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb05006.x · Cited by 337
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Hoff, V., Schilsky, R. L., Reichert, C. M., Rl, R., Rozencweig, M., Rc, Y., & Muggia, F. M. (1980) · PubMed · Cited by 336
Cdk inhibitors: on the threshold of checkpoints and development
Elledge, S. J., & Harper, J. W. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90055-8 · Cited by 320
Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link
Huang, H., Zhu, L., Reid, B. R., Drobny, G. P., & Hopkins, P. B. (1995) · Science · doi:10.1126/science.270.5243.1842 · Cited by 314
Almasan, A., Yin, Y., Kelly, R. E., Lee, E. Y., Bradley, A., Li, W., Bertino, J. R., & Wahl, G. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5436 · Cited by 296
A cell cycle-regulated inhibitor of cyclin-dependent kinases.
Hengst, L., Dulic, V, Slingerland, J. M., Lees, E., & Reed, S. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5291 · Cited by 287
Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation.
Lee, E. Y., Hu, N., Yuan, S. S., Cox, L. A., Bradley, A., Lee, W. H., & Herrup, K. (1994) · Genes & Development · doi:10.1101/gad.8.17.2008 · Cited by 285
N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells
Ferrari, G., Yan, C., & Greene, L. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-04-02857.1995 · Cited by 269
Park, D. S., Levine, B., Ferrari, G., & Greene, L. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-23-08975.1997 · Cited by 265
Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM.
Enoch, T., & Norbury, C. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89093-3 · Cited by 261
Park, D. S., Farinelli, S. E., & Greene, L. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8161 · Cited by 250
Motokura, T., & Arnold, A. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80334-x · Cited by 232
DeCaprio, J. A., Furukawa, Y., Ajchenbaum, F., Griffin, J. D., & Livingston, D. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1795 · Cited by 232
Nerve growth factor prevents experimental cisplatin neuropathy
Apfel, S. C., Arezzo, J. C., Lipson, L., & Kessler, J. A. (1992) · Annals of Neurology · doi:10.1002/ana.410310114 · Cited by 210
Farinelli, S., & Greene, L. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01150.1996 · Cited by 201
Internucleosomal DNA cleavage and neuronal cell survival/death
Batistatou, A., & Greene, L. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.3.523 · Cited by 193
Mollman, J. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220210 · Cited by 163
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158
Neurotoxic Effects of Cisplatin Therapy
Walsh, T. J., Clark, A. W., Parhad, I. M., & Green, W. R. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510230045013 · Cited by 142
Sidle, A., Palaty, C., Dirks, P., Wiggan, O., Kiess, M., Gill, R. M., Wong, A. K., & Hamel, P. A. (1996) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239609106585 · Cited by 141
Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy
Gao, W., Dybdal, N. O., Shinsky, N., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380108 · Cited by 134
Zheng, J., Stewart, R., & Gao, W. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-07-05079.1995 · Cited by 132
Allday, M. J., Inman, G. J., Crawford, D., & Farrell, P. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00182.x · Cited by 125
Tomiwa, K., Nolan, C., & Cavanagh, J. (1986) · Acta Neuropathologica · doi:10.1007/bf00688308 · Cited by 98
Genetic instability as a consequence of inappropriate entry into and Progression through S-phase
Almasan, A., Linke, S. P., Paulson, T. G., Huang, L.-C., & Wahl, G. M. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690212 · Cited by 91
Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy
Barajon, I., Bersani, M., Quartu, M., et al. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0050 · Cited by 84
Progressive paresthesias after cessation of therapy with very high-dose cisplatin
Grunberg, S. M., Sonka, S., Stevenson, L. L., et al. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694340 · Cited by 82
Schmidt, Y., Unger, J. W., Bartke, I., & Reiter, R. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90054-3 · Cited by 81
Malgrange, B., Delrée, P., Rigo, J., Baron, H., & Moonen, G. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90151-1 · Cited by 79
CDKs and cyclins in transition(s)
Fisher, R. P. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80106-2 · Cited by 77
Konings, P. N. M., Makkink, W. K., Delft, A. M. L. V., & Ruigt, G. F. (1994) · Brain Research · doi:10.1016/0006-8993(94)91873-2 · Cited by 72
Hayakawa, K., Sobue, G., Itoh, T., & Mitsuma, T. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00744-6 · Cited by 70
Hol, E. M., Gispen, W. H., & Bär, P. R. (1995) · Peptides · doi:10.1016/0196-9781(95)00017-e · Cited by 64
Zheng, J. L., Stewart, R. R., & Gao, W. (1995) · Journal of Neurobiology · doi:10.1002/neu.480280306 · Cited by 61
TrkA Activation Is Sufficient to Rescue Axotomized Cholinergic Neurons
Lucidi‐Phillipi, C. A., Clary, D. O., Reichardt, L. F., & Gage, F. H. (1996) · Neuron · doi:10.1016/s0896-6273(00)80084-7 · Cited by 59
Effect of cisplatin and ACTH4–9 on neural transport in cisplatin induced neurotoxicity
Russell, J. W., Windebank, A. J., McNiven, M. A., Brat, D. J., & Brimijoin, W. S. (1995) · Brain Research · doi:10.1016/0006-8993(95)00100-5 · Cited by 53
Self-citationvan der Hoop, R. G., Hamers, F. P. T., Neijt, J. P., Veldman, H., Gispen, W. H., & Jennekens, F. G. I. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90259-3 · Cited by 35
ACTH/MSH like peptides in the treatment of cisplatin neuropathy
Gispen, W. H., Hamers, F. P. T., Vecht, C. J., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90205-w · Cited by 28
The biology of radioresistance: similarities, differences and interactions with drug resistance
Powell, S. N., & Abraham, E. H. (1993) · Cytotechnology · doi:10.1007/bf00744671 · Cited by 24
The retinoblastoma gene: its role in cell cycle and cancer.
Giordano, A., & Kaiser, H. E. (1996) · PubMed · Cited by 11
The biology of radioresistance: similarities, differences and interactions with drug resistance
Powell, S. N., & Abraham, E. H. (1994) · Springer eBooks · doi:10.1007/978-94-011-0826-3_16 · Cited by 4
Cited by
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,558
Chemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Self-citationChemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Self-citationThe harlequin mouse mutation downregulates apoptosis-inducing factor
Klein, J. A., Longo-Guess, C. M., Rossmann, M. P., Seburn, K. L., Hurd, R. E., Frankel, W. N., Bronson, R. T., & Ackerman, S. L. (2002) · Nature · doi:10.1038/nature01034 · Cited by 605
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Metadata
- Authors
- Gill, J. S., & Windebank, A. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-06-15
- Volume
- 101
- Issue
- 12
- Pages
- 2842-2850
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2009929398
- Cited by
- 278
- References
- 57
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.